3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
pembrolizumab
1254
Specimen Handling
869
Carboplatin
818
Magnetic Resonance Spectroscopy
804
Cyclophosphamide
795
Cisplatin
716
Nivolumab
648
Paclitaxel
623
Radiotherapy
567
Gemcitabine
565
Biopsy
529
Bevacizumab
468
Dexamethasone
434
fludarabine
404
Docetaxel
373
venetoclax
366
Oxaliplatin
362
Capecitabine
353
Fluorouracil
352
atezolizumab
341
Rituximab
327
durvalumab
326
Doxorubicin
313
Radiosurgery
306
Pemetrexed
303
Drug Therapy
295
Standard of Care
292
Ipilimumab
290
Etoposide
280
Radiation
278
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
olaratumab
×
1 year
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts